Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oneness Biotech CoLUX:ONEA 57 Cyclically Adjusted PS Ratio is 138.82 as of Jul. 28, 2026, which is 76% below its 10-year median of 571.22. GuruFocus rates LUX:ONEA with a GF Score™ of 57/100 and a GF Value™ of $47.00. The stock has 4 warning signs investors should review. Among 537 Biotechnology companies, Oneness Biotech Co ranks worse than 96.28% on this metric.
The historical rank and industry rank for Oneness Biotech Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
LUX:ONEA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 120.48 Med: 571.22 Max: 4451.54
Current: 120.48
During the past years, Oneness Biotech Co's highest Cyclically Adjusted PS Ratio was 4451.54. The lowest was 120.48. And the median was 571.22.
LUX:ONEA's Cyclically Adjusted PS Ratio is ranked worse than 96.28% of 537
companies
in the Biotechnology industry
Industry Median: 5.59
vs LUX:ONEA: 120.48
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Oneness Biotech Co's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.012. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.17 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Oneness Biotech Co (LUX:ONEA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Oneness Biotech Co Cyclically Adjusted PS Ratio Related Terms
Oneness Biotech Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co Cyclically Adjusted PS Ratio Chart
LUX:ONEA vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Oneness Biotech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's Cyclically Adjusted PS Ratio falls into.
Oneness Biotech Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Oneness Biotech Co's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 138.82 mean?
Oneness Biotech Co (LUX:ONEA) has a Cyclically Adjusted PS Ratio of 138.82 as of Jul. 28, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Oneness Biotech Co and its competitors. This is 76% below median its historical median of 571.22. Over the past decade, Oneness Biotech Co's Cyclically Adjusted PS Ratio has ranged from 120.48 to 4,451.54. According to the industry distribution chart, Oneness Biotech Co ranks #517 out of 537 companies in the Biotechnology industry, placing it in the top 96.3%.
Is Oneness Biotech Co's Cyclically Adjusted PS Ratio too high?
Oneness Biotech Co's current Cyclically Adjusted PS Ratio of 138.82 is 76% below median its 10-year median of 571.22. Over the past 10 years, this metric has ranged from a low of 120.48 to a high of 4,451.54. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.59. Oneness Biotech Co's value of 138.82 is 2383.4% above this industry median. Based on the distribution chart, Oneness Biotech Co ranks #517 out of 537 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #517 out of 537 companies for Cyclically Adjusted PS Ratio. This places Oneness Biotech Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.59. Oneness Biotech Co's value of 138.82 is 2383.4% above this benchmark. Historically, Oneness Biotech Co's own Cyclically Adjusted PS Ratio has ranged from 120.48 to 4,451.54 over the past decade. While the company's 10-year median is 571.22 vs. the industry median of 5.59, Oneness Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.59, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current Cyclically Adjusted PS Ratio of 138.82 is 2383.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Oneness Biotech Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current Cyclically Adjusted PS Ratio is 138.82, which is 76% below median its own 10-year median of 571.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current Cyclically Adjusted PS Ratio of 138.82. The stock's GF Value™ is $47.00, compared to a current price of $23.60 — trading 49.8% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 138.82, which is 76% below median its 10-year median of 571.22 and 2383.4% above the Biotechnology industry median of 5.59. Oneness Biotech Co's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current Cyclically Adjusted PS Ratio is 138.82 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 49.8% below its estimated GF Value™ of $47.00.
Key valuation signals for LUX:ONEA:
Cyclically Adjusted PS Ratio: 138.82 (76% below median its 10-year median of 571.22)
GF Value™: $47.00 vs. price of $23.60 (49.8% below fair value)
Industry Position: 2383.4% above the Biotechnology median (#517 of 537)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
57GF Score
Get the complete analysis for LUX:ONEA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
